Based on these data, trastuzumab plus chemotherapy was FDA-approved for patients with previously untreated, HER2-positive, metastatic gastric or GEJ adenocarcinoma on 20 October 2010 [112]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.